Literature DB >> 29717400

Crizotinib-induced simultaneous multiple cardiac toxicities.

Takuya Oyakawa1, Nao Muraoka2, Kei Iida2, Masatoshi Kusuhara3, Takahisa Kawamura4, Tateaki Naito4, Toshiaki Takahashi4.   

Abstract

Crizotinib is a receptor tyrosine kinase inhibitor that has several targets, including c-ros oncogene 1 and the MET proto-oncogene. Considering its known cardiac toxicity, bradycardia is often investigated following treatment with crizotinib. Our patients had bradycardia, QT prolongation, ventricular rhythm, ventricular fibrillation, and pericarditis simultaneously. The cardiotoxicity of crizotinib can sometimes be simultaneous; thus, intensive observation is needed.

Entities:  

Keywords:  Cardiac toxicity; Cardio-oncology; Crizotinib; Lung cancer; MET

Mesh：

Substances：

Year:  2018        PMID： 29717400     DOI： 10.1007/s10637-018-0605-x

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  5 in total

1.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

2.  Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Giorgio Scagliotti; Joachim von Pawel; Silvia Novello; Rodryg Ramlau; Adolfo Favaretto; Fabrice Barlesi; Wallace Akerley; Sergey Orlov; Armando Santoro; David Spigel; Vera Hirsh; Frances A Shepherd; Lecia V Sequist; Alan Sandler; Jeffrey S Ross; Qiang Wang; Reinhard von Roemeling; Dale Shuster; Brian Schwartz
Journal:  J Clin Oncol       Date:  2015-07-13       Impact factor: 44.544

Review 3.  Cellular and molecular mechanisms of HGF/Met in the cardiovascular system.

Authors:  Simona Gallo; Valentina Sala; Stefano Gatti; Tiziana Crepaldi
Journal:  Clin Sci (Lond)       Date:  2015-12       Impact factor: 6.124

4.  Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer.

Authors:  Hari Deshpande; Vicky Marler; Julie Ann Sosa
Journal:  Onco Targets Ther       Date:  2011-12-09       Impact factor: 4.147

5.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter
Journal:  Eur Heart J       Date:  2016-08-26       Impact factor: 29.983
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.